Conversely, inhibiting SPHK1 can sensitize CML and pancreatic cancer cells to the proapoptotic effects of imatinib and gemcitabine, respectively, apparently by reducing the S1P/ceramide ratio [40, 41]. The gene discussed is MBTPS1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.